Roivant Sciences Ltd. (NASDAQ:ROIV)
| Market Cap | 24.16B+110.8% |
| Revenue (ttm) | n/a-67.6% |
| Net Income | n/a+45.7% |
| EPS | n/a+37.1% |
| Shares Out | 722.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,467,670.273 |
| Open | 34.13 |
| Previous Close | 34.75 |
| Day's Range | 33.32 - 34.56 |
| 52-Week Range | 15.90 - 42.50 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 46.75(+39.76%) |
| Earnings Date | n/a |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About ROIV
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ROIV stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ROIV holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ROIV's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ROIV Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ROIV patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ROIV from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ROIV
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $554.94M |
| VBVanguard Morningstar Small-Cap ETF | $401.32M |
| XMMOInvesco S&P MidCap Momentum ETF | $245.65M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $230.30M |
| VXFVanguard Extended Market ETF | $181.43M |
| MDYState Street SPDR S&P MIDCAP 400 ETF Trust | $142.53M |
Estimated from each fund’s disclosed top holdings × AUM
ROIV Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ROIV’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score